Skip to main content
SpringerLink
Log in

The Hypertension in the Very Elderly Trial (HYVET)

Rationale, Methodology and Comparison with Previous Trials

  • Review Article
  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

The Hypertension in the Very Elderly Trial (HYVET) is a multicentre, open, randomised, controlled trial. The aim of this trial is to investigate the effect of active treatment on stroke incidence in hypertensive patients over the age of 80 years. Secondary end-points include total cardiovascular mortality and morbidity.

Entry criteria include a sustained sitting systolic blood pressure of 160 to 219mm Hg plus a sustained sitting diastolic pressure of 95 to 109mm Hg. Also required is a standing systolic blood pressure of at least 140mm Hg. Patients must give their informed consent, and be free of congestive heart failure requiring treatment, gout, renal failure or a recent cerebral haemorrhage. Patients are to be randomised to 3 groups — (i) no treatment; (ii) treatment with a diuretic [bendroflumethiazide (bendrofluazide)]; or (iii) treatment with an angiotensin converting enzyme (ACE) inhibitor (lisinopril).

Starting dosage for bendroflumethiazide and lisinopril is 2.5 mg/day. In order to achieve goal sitting systolic and diastolic blood pressures (< 150/80mm Hg), a doubling of the dosage is allowed. Furthermore, slow release diltiazem (120 mg/day increasing to 240 mg/day if required) may be added to the medication of the actively treated groups. These drugs have been chosen as inexpensive and appropriate representatives of their therapeutic classes.

700 patients in each group (a total of 2100) will be sufficient to detect a 40% difference in cerebrovascular events between no treatment and active treatment (α = 0.01, 1−β = 0.90). These numbers will also detect a difference in total mortality of 25% and in cardiovascular mortality of 35%.

The pilot phase of the trial has been started with support from the British Heart Foundation. Centres which are interested in taking part should contact C. J. Bulpitt or any of the other authors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Office of Population Censuses and Surveys. Mortality statistics 1986. London: HMSO, 1988. Series DH2 No. 13

  2. Agner E. Natural history of angina pectoris, possible previous myocardial infarction and intermittent claudication during the eighth decade: a longitudinal epidemiologic study. Acta Med Scand 1981; 210: 271–6

    Article  PubMed  CAS  Google Scholar 

  3. World Health Organisation. Preventing disability in the elderly. Copenhagen: WHO Regional Office for Europe, 1982. EURO Reports and Studies, No. 65

    Google Scholar 

  4. Shekelle RB, Ostfeld AM, Klawans HL. Hypertension and risk of stroke in an elderly population. Stroke 1974; 5: 71–5

    Article  PubMed  CAS  Google Scholar 

  5. Garland C, Barrett-Connor E, Suarez L, et al. Isolated systolic hypertension and mortality after age 60 years: a prospective population based study. Am J Epidemiol 1983; 118: 365–76

    PubMed  CAS  Google Scholar 

  6. Proportional hazards analysis of risk factors for coronary heart disease in individuals aged 65 years or older: the Framingham Heart Study. J Am Geriatr Soc 1988; 36: 1023–8

  7. Miall WE, Chinn S. Screening for hypertension: some epidemiological considerations. BMJ 1974; 3: 595–600

    Article  PubMed  CAS  Google Scholar 

  8. Mattila K, Haavisto M, Rajala S, et al. Blood pressure and survival in the very old. BMJ 1988; 296: 887–9

    Article  PubMed  CAS  Google Scholar 

  9. Langer RD, Ganiate TG, Barrett-Connor E. Paradoxical survival of elderly men with high blood pressure. BMJ 1989; 298: 1356–7

    Article  PubMed  CAS  Google Scholar 

  10. Bulpitt CJ, Fletcher AE. Aging, blood pressure and mortality. J Hypertens 1992; 10 Suppl. 7: S45–9

    CAS  Google Scholar 

  11. Bulpitt CJ, Fletcher AE. Prognostic significance of blood pressure in the very old: implications for the treatment decision. Drugs Aging 1994; 5(3): 184–191

    Article  PubMed  CAS  Google Scholar 

  12. Coope JN, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293: 1145–51

    Article  PubMed  CAS  Google Scholar 

  13. Medical Research Council Working Party. MRC trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–12

    Article  Google Scholar 

  14. Amery A, Birkenhäger W, Brixko P, et al. Efficacy of antihypertensive drug treatment according to age, sex, blood pressure and previous cardiovascular disease in patients over the age of 60. Lancet 1986; 2: 589–92

    Article  PubMed  CAS  Google Scholar 

  15. Dahlof B, Lindholm LH, Hanson L, et al. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–5

    Article  PubMed  CAS  Google Scholar 

  16. SHEP Co-operative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265: 3255–64

    Article  Google Scholar 

  17. Emeriau JP. What is the clinical relevance of isolated systolic hypertension. Drugs Aging 1992; 2: 147–52

    Article  PubMed  CAS  Google Scholar 

  18. Amery A, Birkenhäger WH, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1: 1349–54

    Article  PubMed  CAS  Google Scholar 

  19. Dahlof BL, Ekbom T, Oden AS, et al. Stroke: prevention in elderly hypertensives not solely dependent on reduced blood pressure — insights from STOP-Hypertension. Presentation at 14th Scientific Meeting of ISH, Madrid 1992

  20. Petrie JC, O’Brien ET, Littler WA, et al. British Hypertension Society recommendations on blood pressure measurement. BMJ 1986; 293: 611–5

    Article  PubMed  CAS  Google Scholar 

  21. Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing 1972; 1: 233–8

    Article  PubMed  CAS  Google Scholar 

  22. Amery A, Birkenhäger W, Bulpitt CJ, et al. Syst-Eur: a multicentre trial on the treatment of isolated systolic hypertension in the elderly — objectives, protocol, and organization. Aging Clin Exp Res 1991; 3: 287–302

    CAS  Google Scholar 

  23. World Health Organisation ICD10. International statistical classification of diseases and related health problems, vol 1. 10th rev. Geneva: WHO, 1992

    Google Scholar 

  24. Aho K, Harmsen P, Hatano S, et al. Cerebrovascular disease in the community: results of a WHO collaborative study. Bull World Health Organ 1980; 58: 113–30

    PubMed  CAS  Google Scholar 

  25. Genton E, Barnet HJM, Fields WS, et al. Cerebral ischemia: the role of thrombosis and antithrombotic therapy. Joint Committee for Stroke Resources. Stroke 1977; 8: 150–75

    Article  PubMed  CAS  Google Scholar 

  26. Heyman A, Leviton A, Millikan CH, et al. Transient focal cerebral ischemia: epidemiological and clinical aspects. Stroke 1977; 5: 277–87

    Google Scholar 

  27. Rose GA, Blackburn H. Méthodes d’enquête sur les maladies cardio-vasculaires. Genève: Organisation Mondiale de la Santé; 1969

    Google Scholar 

  28. Grimley Evans J. Blood pressure and stroke in an elderly English population. J Epidemiol Community Health 1987; 41: 275–82

    Article  Google Scholar 

  29. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977; 64: 191–9

    Article  Google Scholar 

  30. O’Brien PC, Flemming TE. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549–56

    Article  PubMed  Google Scholar 

  31. Carlsen JE, K0ber L, Torp-Pedersen C, et al. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300: 975–8

    Article  PubMed  CAS  Google Scholar 

  32. Bulpitt CJ. A risk-benefit analysis for the treatment of hypertension. Postgrad Med J 1993; 69: 764–74

    Article  PubMed  CAS  Google Scholar 

  33. Dollery C, Boobis AR, Burley B, et al. Bendrofluazide. In: Therapeutic drugs, vol. 1. Edinburgh: Churchill Livingstone, 1991: B19–B26

    Google Scholar 

  34. Dollery C, Boobis AR, Burley B, et al. Hydrochlorothiazide. In: Therapeutic drugs, vol. 1. Edinburgh: Churchill Livingstone, 1991: H50–H54

    Google Scholar 

  35. Dollery C, Boobis AR, Burley B, et al. Lisinopril. In: Therapeutic drugs, vol. 2. Edinburgh: Churchill Livingstone, 1991: L39–L43

    Google Scholar 

  36. Whelton A, Miller WE, Dunne B, et al. Once daily lisinopril compared with twice daily captopril in treatment of mild to moderate hypertension: assessment of office and ambulatory blood pressure. J Clin Pharmacol 1990; 30: 1074–80

    PubMed  CAS  Google Scholar 

  37. Whelton A, Dunne B, Glazer N, et al. Twenty four hour blood pressure effect of once daily lisinopril, enalapril, and placebo in patients with mild to moderate hypertension. J Hum Hypertens 1992; 6: 325–31

    PubMed  CAS  Google Scholar 

  38. Pool JI, Gennari J, Goldstein R, et al. Controlled multicentre study of antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril and hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 1987; 9 (3 Suppl.): S36–S42

    Article  PubMed  Google Scholar 

  39. Bolzano K, Arriaga J, Bernai R, et al. The antihypertensive effect of lisinopril compared to atenolol in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1987; 9 (13 Suppl.): S43–7

    Article  PubMed  Google Scholar 

  40. Chrysant SG, Chrysant C, Trus J, et al. The antihypertensive effectiveness of lisinopril and metoprolol alone and in combination with other drugs. Curr Ther Res 1989; 45: 238–44

    Google Scholar 

  41. Pannier BE, Garabedien VG, Madonna O, et al. Lisinopril v atenolol: decrease in systolic versus diastolic blood pressure with converting enzyme inhibition. Cardiovasc Drugs Ther 1991; 5: 755–82

    Article  Google Scholar 

  42. Lees KR, Reid JL. Lisinopril and nifedipine: no acute interaction in normotensives. Br J Clin Pharmacol 1988; 25: 307–13

    Article  PubMed  CAS  Google Scholar 

  43. Morlin C, Bagliro H, Boeijinga JIC, et al. Comparative trial of lisinopril and nifedipine in mild to severe essential hypertension. J Cardiovasc Pharmacol 1987; 9: 48–52

    Article  Google Scholar 

  44. Laher MS. Lisinopril in elderly patients with hypertension, long term effects on renal and metabolic function. Drugs 1990; 39 (2 Suppl.): 55–63

    Article  PubMed  Google Scholar 

  45. Laher MS, Natin D, Rao SK, et al. Lisinopril in elderly patients with hypertension. J Cardiovasc Pharmacol 1987; 9 (3 Suppl.): 69–71

    Article  Google Scholar 

  46. Herpin D, Conte D. Assessment of the antihypertensive effect of lisinopril using 24 hour ambulatory monitoring. J Hum Hypertens 1989; 3: 11–5

    PubMed  Google Scholar 

  47. Zachariah PK, Bonnel G, Chrysant SG, et al. Antihypertensive efficacy of lisinopril: ambulatory blood pressure monitoring. Am J Hypertens 1988; 1: 274S–9S

    PubMed  CAS  Google Scholar 

  48. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients — meta-analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95–100

    PubMed  Google Scholar 

  49. Hansson L, Svensson A, Dahlöf B, et al. Drug treatment of hypertension. In: Robertson JIS, editor. Handbook of hypertension: clinical aspects of essential hypertension, vol. 15, Amsterdam: Elsevier, 1992: 655–708

    Google Scholar 

  50. Hansson L, Dahlöf B, Himmelman A, et al. ACE inhibitors in treatment of essential hypertension. In: Nicholls G, Robertson JIS, editors. Renin textbook, vol.91, London: Gower Medical, 1992: 1–24

    Google Scholar 

  51. Marner R, Vandapapeliere P, DeVriese G. Safety and efficacy of lisinopril in elderly patients with mild to moderate hypertension. J Hum Hypertens 1989; 3: 163–7

    Google Scholar 

  52. Murray NH. Duration of ACE inhibitor inhibition: implication for tolerability. Cardiology 1991; 79 (1 Suppl.): 22–9

    Article  PubMed  Google Scholar 

  53. Rush JE, Lyle PA. Safety and tolerability of lisinopril in clinical trials. Am J Med 1988; 85(Suppl. 3B): 99–107

    Google Scholar 

  54. Moyse C, Higgins TJC. Safety of long term use of lisinopril for congestive heart failure. Am J Cardiol 1992; 70: 91C–97C

    Article  Google Scholar 

  55. Dollery C, Boobis AR, Burley B, et al. Diltiazem (hydrochloride). In: Therapeutic drugs. Edinburgh: Churchill Livingstone, 1991; 1: D143–D148

    Google Scholar 

  56. Kates RE. Calcium antagonists: pharmacokinetic properties. Drugs 1983; 25: 113–24

    Article  PubMed  CAS  Google Scholar 

  57. Smith MS, Verghese CP, Shand DG, et al. Pharmacokinetic and pharmacodynamic effects of diltiazem. Am J Cardiol 1983; 51: 1369–74

    Article  PubMed  CAS  Google Scholar 

  58. Walker G. APBI Data Sheet Compendium 1993–1994. Association of British Pharmaceutical Industries. London: Datapharm Publications, 1993

    Google Scholar 

  59. Schulte KL, Meyer-Sabellek WA, Distler A, et al. Long term treatment with diltiazem and nifedipine in essential hypertension. J Hypertens 1984; 2: 93

    Article  Google Scholar 

  60. Yamakado T, Oonishi N, Kando S, et al. Effects of diltiazem on cardiovascular responses during exercise in systemic hypertension and comparison with propranolol. Am J Cardiol 1983; 53: 1023–7

    Article  Google Scholar 

  61. Letzel H, Bluemner E. Dose-response curves in antihypertensive combination therapy: results of a controlled clinical trial. J Hypertens 1990; 8 (4 Suppl.): S83–S86

    CAS  Google Scholar 

  62. Hansson L, Dahlöf B. Calcium antagonists in the treatment of hypertension: state of the art. J Cardiovasc Pharmacol 1990; 15 (4 Suppl.): S71–S75

    Article  PubMed  Google Scholar 

  63. McGraw BF, Walker ST, Hemberger JA, et al. Clinical experience with diltiazem in Japan. Pharmacotherapy 1982; 2: 156–61

    PubMed  CAS  Google Scholar 

  64. Waller PC, Inman WHW. Diltiazem and heart block. Lancet 1981; 1: 617

    Google Scholar 

  65. Prida XE, Gelman JS, Feldman RL, et al. Comparison of diltiazem and nifedipine alone and in combination in patients with coronary artery spasm. J Am Coll Cardiol 1987; 9: 412–9

    Article  PubMed  CAS  Google Scholar 

  66. Klinke WP, Kvill L, Dempsey EE, et al. A randomised double blind comparison of diltiazem and nifedipine in stable angina. J Am Coll Cardiol 1988; 12: 1562–7

    Article  PubMed  CAS  Google Scholar 

  67. Pepine CJ, Joyal M, Cremer KF, et al. Haemodynamic effects of glycerin combined with diltiazem in patients with coronary artery disease. Am J Med 1984; 76(Suppl. 6A): 47–51

    PubMed  CAS  Google Scholar 

  68. Pertz JE, Borda L, Schuchlei BR, et al. Inotropic and chronotropic effect of vasodilators. J Pharmacol Exp Ther 1982; 221: 609–13

    Google Scholar 

  69. Walsh RA, Bradke FR, O’Rourke RA. Differential effects of systemic and intracoronary calcium channel blocking agents on global and regional left ventricular function in conscious dogs. Am Heart J 1981; 102: 341–50

    Article  PubMed  CAS  Google Scholar 

  70. Walsh RA, Porter CB, Starling MR, et al. Salutary haemodynamic effects of intravenous and oral diltiazem in severe congestive cardiac failure. Circulation 1982; 66 (Suppl. 2, Pt 2): II–138

    Google Scholar 

  71. Bulpitt CJ. In: Bulpitt CJ, editor. Randomised controlled clinical trials. The Hague: Martinus Nijhoff, 1983: 64–7

  72. Bulpitt CJ. Definition, prevalence and incidence of hypertension in the elderly. In: Amery A and Staessen J, editors. Handbook of hypertension: hypertension in the elderly, vol. 12, Amsterdam: Elsevier, 1989: 155–69

    Google Scholar 

  73. Sever P, Beevers G, Bulpitt CJ, et al. Management guidelines in essential hypertention: report of the second working party of the British Hypertension Society. BMJ 1993; 306: 983–7

    Article  PubMed  CAS  Google Scholar 

  74. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1993; 153: 154–83

    Article  Google Scholar 

  75. WHO/ISH. 1993 Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension Meeting. J Hypertens 1993; 11: 905–18

    Article  Google Scholar 

  76. Staessen J, Fagard R, Lijinen P, et al. Review of the major intervention trials in the elderly. Cardiovasc Drugs Ther 1990; 4: 1237–42

    Article  Google Scholar 

  77. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principle results. BMJ 1985; 2: 97–104

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Geriatric Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London, W12 0NN, England

    Christopher J. Bulpitt, Sara Lightowlers & Alison Palmer

  2. Department of Epidemiology and Population Sciences, London School of Hygiene and Tropical Medicine, London, England

    Astrid E. Fletcher

  3. Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium

    Antoon Amery & Jan Staessen

  4. The Waterhouse, Bollington, Cheshire, England

    John Coope

  5. Nuffield Department of Clinical Medicine, Geriatric Medicine Division, Radcliffe Infirmary, Oxford, England

    J. Grimley Evans

  6. Royal College of Surgeons in Ireland, Dublin, Ireland

    Kevin O’Malley

  7. University Department of Medicine/Elderly, The Glenfield Hospital, Leicester, England

    John Potter

  8. Department of Clinical Pharmacology, St Mary’s Hospital Medical School, Queen Elizabeth the Queen Mother Wing, London, England

    Peter Sever

  9. Department of Health Care/Elderly, King’s College School of Medicine, King’s College Hospital (Dulwich), London, England

    Cameron Swift

Authors
  1. Christopher J. Bulpitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Astrid E. Fletcher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antoon Amery
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John Coope
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Grimley Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sara Lightowlers
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kevin O’Malley
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alison Palmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. John Potter
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Peter Sever
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jan Staessen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Cameron Swift
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bulpitt, C.J., Fletcher, A.E., Amery, A. et al. The Hypertension in the Very Elderly Trial (HYVET). Drugs & Aging 5, 171–183 (1994). https://doi.org/10.2165/00002512-199405030-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199405030-00003

Keywords

Search

Navigation